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Abstract: Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), still remains one of the
leading causes of death from a single infectious agent worldwide. The high prevalence of this
disease is mostly ascribed to the rapid development of drug resistance to the current anti-TB drugs,
exacerbated by lack of patient adherence due to drug toxicity. The aforementioned highlights the
urgent need for new anti-TB compounds with different antimycobacterial mechanisms of action to
those currently being used. An N-alkyl quinolone; decoquinate derivative RMB041, has recently
shown promising antimicrobial activity against Mtb, while also exhibiting low cytotoxicity and
excellent pharmacokinetic characteristics. Its exact mechanism of action, however, is still unknown.
Considering this, we used GCxGC-TOFMS and well described metabolomic approaches to analyze
and compare the metabolic alterations of Mtb treated with decoquinate derivative RMB041 by
comparison to non-treated Mtb controls. The most significantly altered pathways in Mtb treated
with this drug include fatty acid metabolism, amino acid metabolism, glycerol metabolism, and the
urea cycle. These changes support previous findings suggesting this drug acts primarily on the cell
wall and secondarily on the DNA metabolism of Mtb. Additionally, we identified metabolic changes
suggesting inhibition of protein synthesis and a state of dormancy.
Keywords: decoquinate derivative RMB041; Mycobacterium tuberculosis; tuberculosis; metabolomics;
GCxGC-TOFMS; mechanism of action
1. Introduction
Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), is currently consid-
ered the deadliest infectious disease worldwide [1]. TB causes about 1.3 million deaths
annually, in addition to approximately 300,000 deaths of patients coinfected with the
human immunodeficiency virus (HIV), while newly infecting 10 million people per an-
num [1,2]. Furthermore, the prevalence of multiple-drug resistant (MDR) and extensively
drug resistant (XDR) TB is also on the rise [3,4]. The urgency for developing new anti-TB
drugs that are less expensive, less cytotoxic, and more efficient, as well as being readily
co-administered with HIV treatment, is indisputable. Currently, the first-line treatment for
TB entails a six-month “directly observed treatment short-course” (DOTS), which includes
using isoniazid (INH), ethambutol (EMB), pyrazinamide (PZA), and rifampicin (RIF) in
combination [5]. Infection with MDR- and XDR-TB requires more expensive treatment
approaches, for a longer treatment duration, using drugs that have a higher risk of adverse
side effects [6,7], which in turn leads to poorer patient compliance and subsequently an
escalated increase of drug resistant TB [8]. Further contributing factors to the development
of drug resistant TB include inaccurate diagnosis, unsupervised treatment protocols, and
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poor economic status [9–11],, and in 2020, this was further exacerbated by the COVID-19
pandemic [1,12]. Over the last 50 years, the only new antimycobaterial compounds to be
approved, as last-resort options, are the anti-TB drugs linezolid, bedaquiline, and dela-
manid [3–5,13]. Recently, the WHO and the UN held its first high-level meeting aimed at
initiating an urgent global response to end the TB epidemic by 2030 [1]. However, certain
objectives need to be met before this goal can be achieved. Most importantly, elucidating
the antimycobacterial mechanisms of action of drugs is considered essential and a means to-
wards finding novel Mtb drug compounds and targets [14]. Furthermore, the mechanisms
of drug resistance also need to be fully understood [15]. Equally important is economic
viability, particularly in high-burden countries with insufficient funding for extremely long,
yet mandatory, clinical trials. It is thus beneficial to further investigate already approved
drugs with established pharmacokinetic properties and safety profiles [16].
Decoquinate (DQ), an anticoccidial quinolone used as a broad-spectrum antibiotic,
has gained interest for its efficacy against malaria, toxoplasmosis, and tuberculosis [17],
accompanied by an excellent safety profile [18], high permeability into the cells, and its
relatively low costs [19]. Recently, an N-alkyl DQ derivative (RMB041) showed high ac-
tivity against Mtb (MIC90 = 1.61 µM), with similar in vitro potency to that of ciprofloxacin
(1.5–12 µM), gatifloxacin (0.66–1.3 µM), and moxifloxacin (0.62–1.3 µM) [20]. Its perme-
ability (LogPapp = −4.8, where compounds with values > −5 are considered highly perme-
able [21]) confers a benefit for drug diffusion through the lipid cell wall [22] and penetration
of infected macrophages and granulomatous lesions in the lungs [23,24]. This drug also
shows low cytotoxicity in human fetal lung fibroblasts [25], as well as promising pharma-
cokinetic properties, including an intravenous elimination half-life (t1/2) of 62.3 h in murine
models and a low human intrinsic clearance rate (CLint) (16 µL/min/mg) [2]. The t1/2
is relatively long when compared to that of other well-known anti-TB drugs such as RIF
(7.19 h) [26,27], EMB (3 h) [28], INH (1.7 h) [29], and PZA (1.05 h) [30], whereas the CLint
performs well compared to that of EMB (>75 µL/min/mg) and INH (<22 µL/min/mg)
but less so in comparison to RIF (<10 µL/min/mg) [31]. Drugs with lower CLint and
longer t1/2 require less frequent administration/dosing, which could improve patience
compliance and contribute to lowering the prevalence of drug resistance [32]. Furthermore,
DQ derivative RMB041 could hold the key to shortening the duration of TB treatment and
reduce the current costs of therapy [33]. Considering this, DQ derivative RMB041 is a
promising anti-TB candidate. However, little is known about its antimycobacterial mecha-
nism of action. Contrary to DQ, which primarily targets the ubiquinol-binding pocket, the
RMB041 derivative rather shows activity against the cell wall and DNA metabolism of Mtb
as its primary and secondary targets, respectively [25]. The exact underlying mechanism of
action, however, is yet to be determined.
In this study, a two-dimensional gas chromatography coupled with time-of-flight mass
spectrometry (GCxGC-TOFMS) metabolomics approach, combined with universally con-
nected metabolic libraries and advanced statistical analysis, was used to identify the metabo-
lite markers best differentiating Mtb treated with and without DQ derivative RMB041.
2. Results
2.1. Data Overview
Principal component analysis (PCA) was initially used to get an overview of the
natural grouping of metabolic data (Figure 1). The total variance described by the first
two principal components (PCs) was 52%, of which PC1 accounted for 30.6% and PC2
for 21.4%, respectively. The PCA scores plot of the metabolite data analyzed by GCxGC-
TOFMS shows clear clustering between Mtb treated with DQ derivative RMB041 and
those cultures that were not (Figure 1). The scores plot also shows that the variance of the
treated Mtb group is clearly greater than the controls, as a result of greater variance in the
metabolite concentrations.
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Figure 1. PCA scores plot obtained from GCxGC-TOFMS whole metabolome analysis of Mtb samples
in the presence and absence of DQ derivative RMB041.
2.2. Marker Selection
Based on compliance to the following criteria: a PLS-DA VIP value > 1 [34], a t-test
p-value < 0.05 [35] or an effect size > 0.8 [36], 36 metabolites were selected as markers
best describing the difference between Mtb treated with DQ derivative RMB041 and
untreated Mtb control samples (Figure 2). The metabolites are listed in Table 1, according
to their VIP values.
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Table 1. The selected metabolite markers best describing the variance between the metabolome of Mtb cultured in the















derivative RMB041 Mtb controls
9-Octadecenoic acid (36021) 0.967 (0.192) 0.560 (0.041) 0.000 34.47 2.59 0.73
Myo-Inositol (17268) 0.024 (0.032) 0.020 (0.002) 0.000 5.298 1.99 0.20
Ribitol (15963) 0.318 (0.513) 0.100 (0.005) 0.006 2.098 1.98 2.18
Arabitol (18403) 0.877 (0.962) 0.790 (0.199) 0.010 2.206 1.98 0.11
Eicosanoic acid (28822) 0.018 (0.025) 0.004 (0.001) 0.000 3.968 1.94 3.50
Erythritol (17113) 0.023 (0.027) 0.028 (0.001) 0.001 3.176 1.92 −0.18
N-Acetyl-Lysine (35704) 0.000 (0.000) 0.004 (0.003) 0.009 1.938 1.81 −1.00
9,12-Octadecadienoic acid (17351) 0.578 (0.827) 0.111 (0.008) 0.016 1.835 1.67 4.21
Valine (16414) 0.039 (0.063) 0.022 (0.005) 0.019 1.908 1.65 0.77
Aspartic acid (17053) 0.018 (0.033) 0.013 (0.004) 0.038 1.341 1.65 0.38
Pentadecanoic acid (42504) 0.017 (0.023) 0.004 (0.001) 0.021 1.648 1.64 3.25
Galactose (28260) 0.004 (0.002) 0.011 (0.001) 0.185 0.747 1.57 −0.64
Glutamic acid (16015) 0.024 (0.043) 0.015 (0.006) 0.032 1.549 1.56 0.60
Lysine (18019) 0.016 (0.030) 0.009 (0.006) 0.047 1.291 1.56 0.78
2-Hydroxyglutaric acid (32796) 0.003 (0.004) 0.002 (0.001) 0.037 1.384 1.53 0.50
Proline (26271) 0.022 (0.041) 0.016 (0.013) 0.060 1.202 1.50 0.38
Glycerol-3-phosphate (15978) 0.012 (0.016) 0.007 (0.002) 0.049 1.308 1.47 0.71
Malonic acid (30794) 0.173 (0.213) 0.039 (0.045) 0.249 0.684 1.46 3.44
Glycerol (17754) 0.994 (1.45) 0.633 (0.031) 0.057 1.171 1.44 0.57
Nonadecanoic acid (NSC11914) 0.499 (0.731) 0.055 (0.009) 0.065 1.127 1.41 8.07
Alanine (16977) 0.321 (0.621) 0.207 (0.152) 0.067 1.156 1.40 0.55
Octadecanoic acid (28842) 0.027 (0.034) 0.005 (0.000) 0.068 1.150 1.40 4.40
β-Aminoisobutanoic acid (33094) 0.035 (0.057) 0.014 (0.004) 0.073 1.310 1.38 1.50
γ-Aminobutyric acid (16865) 0.011 (0.018) 0.016 (0.006) 0.085 1.315 1.34 −0.31
Tyrosine (17895) 0.006 (0.012) 0.003 (0.001) 0.147 0.843 1.32 1.00
9-Hexadecenoic acid (59265) 0.105 (0.153) 0.018 (0.003) 0.099 0.975 1.29 4.83
Heptadecanoic acid (32365) 0.052 (0.069) 0.011 (0.002) 0.103 0.975 1.29 3.73
Ribofuranose (33942) 0.003 (0.003) 0.007 (0.002) 0.239 0.653 1.28 −0.57
Glucose (17243) 0.045 (0.031) 0.037 (0.005) 0.174 0.770 1.24 0.22
Isoleucine (17191) 0.018 (0.032) 0.008 (0.008) 0.216 0.702 1.21 1.25
9Z-Octadec-1-ol (73504) 0.026 (0.036) 0.004 (0.003) 0.276 0.601 1.17 5.50
Decanoic acid (30813) 0.008 (0.009) 0.005 (0.001) 0.157 0.836 1.18 0.60
Malic acid (6650) 0.084 (0.127) 0.054 (0.004) 0.172 0.775 1.11 0.56
Ornithine (15729) 0.029 (0.054) 0.025 (0.015) 0.191 0.841 1.09 0.16
Serine (17822) 0.011 (0.021) 0.004 (0.002) 0.151 0.850 1.06 1.75
Threonine (16857) 0.049 (0.088) 0.016 (0.008) 0.173 0.791 0.93 2.06
3. Discussion
In this study we identified a number of significantly altered metabolites induced by the
administration of DQ derivative RMB041 to Mtb culture. In the light of known metabolism
and previous DQ derivative RMB041 findings, the interpretation of these selected metabo-
lite markers, and their associated metabolic pathways, lead to better elucidation of the
antimycobacterial mechanism of action of this drug. The most prominently altered path-
ways (amino acid metabolism, fatty acid metabolism, pentose phosphate pathway (PPP),
and the urea cycle) are mapped in Figure 3.
Preeminent in the Mtb treated with DQ derivative RMB041 is the elevation of many
of the even and odd saturated fatty acids of between 10 to 20 carbons (C10:0-C20:0). This
was also true for the ∆9-mono-unsaturated fatty acids (∆9 C18:19), as previously men-
tioned, and 9-hexadecenoic (∆9C16:1), in addition to the ∆9,12-poly-unsaturated fatty acid
9,12-octadecenoic (∆9,12 C18:2). These indicate a strong upregulated synthesis towards cell
wall repair [37] and an accumulation thereof due to DQ derivative RMB041 inhibiting this
process, which strengthens previous findings, suggesting the antimycobacterial activity of
DQ derivative RMB041 targeting the cell wall [25]. The distinctly multilaminate cell wall of
Mtb consists of a peptidoglycan (PG) layer covalently attached to arabinogalactan (AG) [38],
which itself attaches to mycolic acids. Interspersed is the mycobacterial plasma membrane,
consisting of glycerophospholipids and glycerolipids, phosphatidyl myo-inositol manno-
sides (PIM), lipomannans (LM), and lipoarabinomannans (LAM) [39], all of which are
considered critical for maintaining cell wall integrity [40], and PIM, which contributes to the
low permeability of the cell envelope and intrinsic tolerance to antibiotics [41]. The synthe-
sis of PIM requires myo-inositol and glycerol-3-phosphate (glycerol-3P), which were also
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elevated in this study. Myo-inositol is produced via the conversion of glucose-6-phosphate
(glucose-6P) to myo-inositol 1-phosphate prior to dephosphorylation by myo-inositol
monophosphate phosphatase [42]. Glycerol-3P is acetylated to produce phosphatidate [43],
which serves as the precursor for all glycerolipids [44]. The saturated fatty acids identified
in this study are synthesized by fatty acid synthase type I (FAS I) and provide fatty acyl-
coenzyme A’s (CoA) to FAS II for elongation [45]. FAS I and FAS II provide acyl-groups
for the synthesis of all cell wall components except for AG [38,46,47]. C14:0, C16:0, C18:0,
∆9 C16:1, and ∆9 C18:1 are considered major fatty acids of the glycerolipids and mycolic
acids [48–50]. C16:0 and C18:0 are oxidized, in the presence of Fe2+, a flavin, NADPH, and
O2, to produce ∆9 C16:1 and ∆9 C18:1, respectively [51,52].
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The mycobacterial cell envelope also plays an important role during survival of
dormant, non-replicating Mtb [53,54]. Mycobacterial membrane proteins recognize stress
conditions [55] and release acyl-CoA’s for rearrangement of the cell wall components [56]
and/or energy metabolism [54]. The expression of the stress response operon requires
continuous energy [57], which is mostly derived from NADH and NADPH released
during fatty acid metabolism [58]. Furthermore, an upregulated glyoxylate shunt, as
opposed to the oxidative half of the tricarboxylic acid (TCA) cycle, along with reduced
glycolysis and altered glycerol metabolism, is associated with an Mtb shift towards a state
of dormancy [59–61]. In our investigation, the elevated levels of malic acid, glucose, sugar
alcohols (with the exception of erythritol), glycerol-3P, and glycerol (Figure 3) suggest that
the same stringent response to dormancy occurs in Mtb treated with the DQ derivative
RMB041. The elevated levels of ribitol and arabitol in the PPP indicate a metabolic flux of
glucose metabolism towards the PPP, and not towards energy production via glycolysis [62].
Furthermore, the decreased concentrations of erythritol confirms the flux towards PPP, and
also the aforementioned PIM synthesis via fructose-6-phosphate (fructose-6P) (Figure 3).
From the results it is evident that fatty acids are most likely the preferred energy source,
further confirmed by the elevated levels of short chain fatty acids (C10:0-C14:0) and
malonic acid, which are derived via β-oxidation of FAS I and FAS II products, in the
presence of NAD+ [63], in the DQ derivative RMB041 treated Mtb. Regeneration of NAD+
is maintained by the increased expression of isocitrate lyase, leading to enhanced flux
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through the glyoxylate shunt [64]. This also reduces the release of CO2, resulting in a direct
carbon flux towards FAS I and FAS II [65], for subsequent energy production [54] and
cell wall remodeling [56]. In the presence of ATP, the resultant CO2, together with NH4
released during amino acid metabolism, are incorporated into the urea cycle via ornithine
(which is elevated in the RMB041 treated Mtb, indicating an upregulated urea cycle)
(Figure 3) [66]. Ornithine serves as the precursor of polyamines, which have previously
been associated with antibiotic-induced mutations [67]. Furthermore, ornithine contributes
to the reclamation of carbon to the TCA cycle via proline and glutamic acid. This can
be obtained via γ-aminobutyric acid (GABA) or via α-ketoglutaric acid (Figure 3) [68].
Notably, DQ derivative RMB041-treated Mtb prefers the latter, which could be explained by
the necessity of α-ketoglutaric acid to incorporate amino acids, such as aspartic acid, into
the TCA cycle [69]. Moreover, NAD(P)H and α-ketoglutaric acid are converted to NAD(P)+
and α-hydroxyglutaric acid [70], which was also found to be elevated in this study. This
might further indicate an imbalanced NAD(P)+/NAD(P)H ratio, supporting the need
for NAD(P)+ for survival of fatty acids as the main energy source, and/or disruption of
the membrane, leading to a disturbed electron transport chain (ETC) and, subsequently
accumulation of NADH [71].
The Mtb non-replicative phase is also associated with a reduction/stagnation of DNA,
RNA, and protein synthesis [72,73]. The accumulation of urea (0.012 vs. 0.002 mg/g;
p = 0.63) in the Mtb treated with DQ derivative RMB041, although not selected as a metabo-
lite marker through the statistical selection process described above, indicates the con-
servation of nitrogen from protein synthesis [74]. Inhibition of protein synthesis would
subsequently disrupt the functionality of membrane proteins and result in an accumulation
of fatty acids as a result of inhibition of cell wall synthesis [75]. Urea could also serve as an
opposing force to prevent osmotic lysis [76] brought about by dehydration as a result of an
altered cell envelope integrity. Aspartic acid, along with ten other amino acids (Table 1),
were found elevated in this study. When considering this in light of the elevated levels
of sugar alcohols detected in the DQ derivative RMB041 treated Mtb group, degradation
of the nucleic acids to purine and pyrimidines is evident [77,78]. Speculatively, the direct
activity of DQ derivative RMB041 on DNA would most likely result in an attempt towards
DNA repair, as was previously indicated by reduced sugar alcohols in Mtb treated with
ciprofloxacin [79]. In this case, however, we saw an accumulation of both amino acids and
sugar alcohols, suggesting DNA replication has not yet been inhibited or repair mecha-
nisms have not yet been activated at the time the cells where harvested. This may, however,
occur at a later stage, or at higher DQ derivative RMB041 concentrations perhaps, but in
the present study, the Mtb treated with DQ derivative RMB041 are most likely still in a
non-replicative state after the irreversible cell envelope damage, which is the primary target
of DQ derivative RMB041 [25]. This is also supported by previous findings suggesting
DNA replication as a secondary target and cell wall metabolism as a primary target of DQ
derivative RMB041 [25].
In a study by Rizvi, et al. [80], oxidative stress, inherent with the shift to a dormant
state in Mtb, resulted in the statistically significant accumulation of the same six (aspartic
acid, valine, threonine, alanine, isoleucine, and lysine) of the ten amino acids identified
as metabolite markers in the DQ derivative RMB041 treated Mtb in our study. The flux of
lysine towards acetic acid, and subsequent fatty acid synthesis, is supported by decreased
levels of its break-down product, N-acetyl-lysine [81]. Furthermore, the branched chain
amino acids, threonine, isoleucine and valine, serve as precursors of propionyl-CoA [82]
for elongation of odd chain fatty acids [83]. Flux towards propionyl-CoA from valine
is furthermore supported by the increased levels of β-aminoisobutanoic acid (BAIBA)
in the DQ derivative RMB041 treated Mtb, whereby the intermediate methyl-malonyl
semialdehyde (MMSA) is the direct precursor of propionyl-CoA [84].
Serine, one of the elevated amino acid markers in the DQ derivative RMB041 treated
Mtb group, also serves as a precursor of phosphatidylserine [85]. Translocation of phos-
phatidylserine on the outer membrane of Mtb has been associated with cell death induced
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by reactive oxygen species (ROS) [86]. ROS are released during the antibiotic-induced
stress response and accumulate when DNA repair is unsuccessful, which in turn results in
the aforementioned dormant phase [87,88]. Altered PG metabolism, as is brought about
by cell wall active antibiotics, has also been linked to changes of growth and division of
bacterial cells [89]. This further suggests irreversible inhibition by DQ derivative RMB041
to the cell envelope, which would result in a continuous activation of the stress response
operon, requiring non-stop energy, supplied by fatty acid metabolism, and, partially, the
TCA cycle, followed by the induction of a dormant state, whereby cell growth and division
is ultimately inhibited.
In summary, this metabolomics approach better characterized the antimycobacte-
rial mechanism of decoquinate RMB041, which not only confirmed previously propose
mechanisms of action but also suggests possible new mechanisms, which could be further
investigated and confirmed using alternative strategies. A possible limitation, however,
is the degradation of thermolabile metabolites into smaller unidentifiable “unknown”
compounds [90].
4. Materials and Methods
4.1. Cell Culture
The reagents used for this investigation were purchased from Sigma–Aldrich, St.
Louis, MO, USA, unless specified otherwise. The microtiter Alamar Blue assay was used
to determine the antimycobacterial sub-minimum inhibitory concentration (IC50) of DQ
derivative RMB041 [91]. Cell cultures were prepared as delineated by Van Breda et al. [92],
with minor modifications. Briefly, Mtb H37Rv ATCC 27294, obtained from the Medical
Research Council (Pretoria, Gauteng, South Africa), was cultured and maintained on
Lowenstein-Jensen (LJ) slants. After four weeks of incubation, a bacterial inoculum of
McFarland 1 (approximately 3 × 108 colony-forming units/mL) was prepared in Middle-
brook 7H9 broth containing 10% OADC (oleic acid, albumin, dextrose, catalase) (Becton,
Dickinson, UK) and 2% PANTA (polymyxin B, amphotericin B, nalidixic acid, trimetho-
prim, and azlocillin) (Becton, Dickinson, UK). The latter shows a negligible impact on Mtb
growth and was added to prevent contamination [93]. In five of the ten aliquots, 4 mL DQ
derivative RMB041 was dissolved in DMSO (150 µM) and further diluted in Middlebrook
7H9 broth to yield a final concentration of 10 µM (0.2% DMSO). A volume of 1 mL of the
prepared inoculum was added to reach a final assay volume of 5 mL, with a bacterial test
concentration of 6 × 10 7 CFU/mL DQ derivative RMB041. The untreated Mtb control
samples were prepared in the remaining five aliquots by adding the bacterial inoculum,
as described above, in 4 mL of Middlebrook 7H9 broth (0.2% DMSO). After 5 days of
incubation at 37 ◦C, the mycobacteria cultures were pelleted by centrifuging the samples
at 4500 rpm for 15 min. These were then washed with 1 mL of PBS and re-pelleted, as
described above. Lastly, the PBS was carefully aspirated, and the samples and the samples
were stored at −80 ◦C until further testing.
4.2. Whole Metabolome Extraction Procedure and Derivatization
The extraction and derivatization procedures were carried out as previously described
by Beukes et al. [94], with slight modifications. Briefly, 8 mg of each of the ten individually
cultured samples were weighed into an Eppendorf tube. As internal standard, 50 µL
3-phenylbutyric acid (0.13125 mg/mL H2O) (Sigma–Aldrich, Lot#536478V) was added,
and a two-phase extraction was performed with chloroform: methanol: water in a 1:3:1
ration (1 mL in each sample). The Eppendorf tubes, containing a 3 mm carbide tungsten
bead in each, were shaken in a vibration mill at 30 Hz for 5 min, followed by centrifugation
at 12,000 rpm for 5 min. After transferring each extract to a GC glass vial, the samples were
dried under a nitrogen stream. Derivatization was achieved by firstly adding 50 µL methox-
amine hydrochloride (Sigma–Aldrich, Lot#BCBP2843V) in pyridine (Lot#S2BC335SV) (at
a final concentration of 15 mg/mL) to the glass vials and heating at 50 ◦C for 90 min,
followed by the addition of 40 µL N,O-bis(trimethylsilyl)trifluoroacetamide (BSTFA) with
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1% trimethylsilyl chloride (TMSCI) (Lot#BCBW2670) and again heating for 60 min at 50 ◦C.
Lastly, each extract was transferred to a 0.1 mL vial insert, which were placed into their
respective GC sample vial prior to injection into the GCxGC-TOFMS.
4.3. GCxGC-TOFMS Analysis
The metabolomics analysis was performed using a 4D Pegasus GCxGC-TOFMS (LECO
Africa (Pty) Ltd., Johannesburg, South Africa), equipped with a Gerstel Multi-Purpose
Sampler (Gerstel GmbH and Co. KG, Mülheim an der Ruhr, Germany) and an Agilent
7890 gas chromatograph (Agilent, Atlanta, GA, USA) coupled to TOFMS (LECO Africa).
The GC-MS parameters were set as previously described [94]. A Rxi-5Sil MS capillary
column was used as the primary column (28.8 m × 0.25 mm internal diameter, 0.25 µm
film thickness, Restec), along with a Rxi-17 capillary column (1.2 m × 0.25 mm internal
diameter, 0.25 µm film thickness). The primary GC oven temperature was set at 70 ◦C for
2 min, and increased at a rate of 4 ◦C/min to a final temperature of 300 ◦C, at which it
was maintained for an additional 2 min. The secondary oven was set at 85 ◦C for 2 min,
increased at 4.5 ◦C/min, to a final temperature of 300 ◦C, at which it was maintained for
4.5 min. Helium, used as a carrier gas, was set to a column flow rate of 1 mL/min and held
at a constant temperature of 270 ◦C. Mass spectrometric data acquisition was carried out
using a filament bias of −70 eV, with a 350 s solvent delay, and an acquisition scanned mass
range of 50–800 m/z at 200 spectra/s. To ensure high internal validity, the samples were
analyzed in random sequence. The analytical performance of GCxGC-TOFMS throughout
the analysis was monitored by adding quality control (QC) samples at the start, in the
middle, and at the end of the sequence.
4.4. Data Processing, Clean-Up, and Statistics
Mass spectral deconvolution (at a signal to noise ratio of 20), peak alignment, and
peak identification was done with ChromaTof software (version 4.32, Leco Corporation,
St. Joseph, MI, USA). For the identification of metabolites, their mass fragment patterns
were compared to those of compounds in the commercially available database, NIST 11,
and an in-house created Organic Acids library, containing previously injected standards.
The quality of the data was evaluated by pretreating the data using a standardized
metabolomics data clean-up procedure [94]. MS total useful signal was used for data
normalization. Considering that the zero values are most likely present in sub-minimum
concentrations rather than being completely absent, they were replaced by a value calcu-
lated as 20% of the minimum detection limit of the entire dataset [95]. An 80% data filter
was then applied to remove compounds that were only detected in two (or less) samples
per group [96]. Log transformation and auto-scaling was applied to balance metabolite
representations. This prevented domination of compounds with higher concentrations
over compounds with lower concentrations [97].
Using MetaboAnalyst (Version 5.0, https:www.metaboanalyst.ca, accessed on 3 May
2021) [98], two multivariate statistic methods were applied: (1) an unsupervised principal
component analysis (PCA) and (2) a supervised partial least squares-discriminant analysis
(PLS-DA) [99]. Additional univariate statistics were also calculated via (1) t-test and (2)
effect size values [36].
5. Conclusions
DQ derivative RMB041 has been previously proposed to act against Mtb, primarily via
inhibition/destruction of its cell wall and inhibition/destruction of DNA as a secondary
target [25]. This metabolomic investigation indicated an altered metabolite profile (drasti-
cally elevated levels of various fatty acids and glycerolipid precursors, amino acids, and
urea cycle intermediates) confirming the aforementioned observations in addition to an
inhibition of protein synthesis and a state of dormancy. This study not only confirms or
improves upon the existing knowledge pool of novel antimycobacterial mechanisms of
actions, but also provides a useful tool for investigating repurposed and/or adjunctive
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drugs against Mtb. Furthermore, a better understanding of the dormancy process as in-
dicted here and could lead to new treatment regimens that reduce the emergence of relapse
and resistance [100].
Author Contributions: Conceptualization, D.T.L. and A.A.A.; data curation, Z.L. and K.E.K.; analysis,
C.B.O., N.L., Z.L. and K.E.K.; visualization, K.E.K.; writing of original draft, K.E.K.; manuscript
editing, D.T.L., A.A.A. and K.E.K. All authors have read and agreed to the published version of
the manuscript.
Funding: This research received no external funding.
Institutional Review Board Statement: Not applicable.
Informed Consent Statement: Not applicable.
Data Availability Statement: Data sharing is not applicable to this article.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Harding, E. WHO global progress report on tuberculosis elimination. Lancet Respir. Med. 2020, 8, 19. [CrossRef]
2. Tanner, L.; Haynes, R.K.; Wiesner, L. An in vitro ADME and in vivo Pharmacokinetic Study of Novel TB-Active Decoquinate
Derivatives. Front. Pharmacol. 2019, 10, 120. [CrossRef]
3. Nguyen, T.V.A.; Anthony, R.M.; Bañuls, A.-L.; Nguyen, T.V.A.; Vu, D.H.; Alffenaar, J.-W.C. Bedaquiline resistance: Its emergence,
mechanism, and prevention. Clin. Infect. Dis. 2018, 66, 1625–1630. [CrossRef]
4. Polsfuss, S.; Hofmann-Thiel, S.; Merker, M.; Krieger, D.; Niemann, S.; Rüssmann, H.; Schönfeld, N.; Hoffmann, H.; Kranzer, K.
Emergence of low-level delamanid and bedaquiline resistance during extremely drug-resistant tuberculosis treatment. Clin. Infect.
Dis. 2019, 69, 1229–1231. [CrossRef]
5. World Health Organization. Consolidated Guidelines on Drug-Resistant Tuberculosis Treatment; World Health Assembly:
Geneva, Switzerland, 2019.
6. Da Silva, P.E.A.; Palomino, J.C. Molecular basis and mechanisms of drug resistance in Mycobacterium tuberculosis: Classical and
new drugs. J. Antimicrob. Chemother. 2011, 66, 1417–1430. [CrossRef]
7. Holmes, K.K.; Bertozzi, S.; Bloom, B.R.; Jha, P. Major Infectious Diseases: Key Messages in Disease Control Priorities, 3rd ed.; The
International Bank for Reconstruction and Development/The World Bank: Washington, DC, USA, 2017; Chapter 1.
8. Vernon, A.; Fielding, K.; Savic, R.; Dodd, L.; Nahid, P. The importance of adherence in tuberculosis treatment clinical trials and its
relevance in explanatory and pragmatic trials. PLoS Med. 2019, 16, e1002884. [CrossRef]
9. Migliori, G.B.; Thong, P.M.; Akkerman, O.; Alffenaar, J.-W.; Álvarez-Navascués, F.; Assao-Neino, M.M.; Bernard, P.V.; Biala, J.S.;
Blanc, F.-X.; Bogorodskaya, E.M. Worldwide effects of coronavirus disease pandemic on tuberculosis services, January–April
2020. Emerg. Infect. Dis. 2020, 26, 2709. [CrossRef] [PubMed]
10. Duarte, R.; Lönnroth, K.; Carvalho, C.; Lima, F.; Carvalho, A.; Muñoz-Torrico, M.; Centis, R. Tuberculosis, social determinants
and co-morbidities (including HIV). Pulmonology 2018, 24, 115–119. [CrossRef]
11. Watermeyer, J.; Penn, C. Community perspectives on tuberculosis care in rural South Africa. HSCC 2019, 27, 182–190. [CrossRef] [PubMed]
12. McQuaid, C.F.; McCreesh, N.; Read, J.M.; Sumner, T.; Houben, R.M.; White, R.G.; Harris, R.C.; Group, C.C.-W. The potential
impact of COVID-19-related disruption on tuberculosis burden. Eur. Respir. J. 2020, 56, 2001718. [CrossRef] [PubMed]
13. World Health Organization. Critically Important Antimicrobials for Human Medicine, 6th ed.; World Health Assembly:
Geneva, Switzerland, 2019.
14. Sloan, D.J.; Lewis, J.M. Management of multidrug-resistant TB: Novel treatments and their expansion to low resource settings.
Trans. R. Soc. Trop. Med. Hyg. 2016, 110, 163–172. [CrossRef]
15. Kolyva, A.S.; Karakousis, P.C. Old and new TB drugs: Mechanisms of action and resistance. In Understanding Tuberculosis—New
Approaches to Fighting against Drug Resistance; InTech: Plantation, FL, USA, 2012; pp. 209–232.
16. Ginsberg, A.M.; Spigelman, M. Challenges in tuberculosis drug research and development. Nat. Med. 2007, 13, 290–294.
[CrossRef] [PubMed]
17. Beteck, R.M.; Seldon, R.; Jordaan, A.; Warner, D.F.; Hoppe, H.C.; Laming, D.; Khanye, S.D. New quinolone-based thiosemicarbazones
showing activity against Plasmodium falciparum and Mycobacterium tuberculosis. Molecules 2019, 24, 1740. [CrossRef] [PubMed]
18. McLoughlin, D.; Chute, M. Efficacy of decoquinate against eleven strains of Eimeria tenella and development of a decoquinate-
resistant strain. Avian Dis. 1971, 15, 342–345. [CrossRef]
19. Beteck, R.M.; Coertzen, D.; Smit, F.J.; Birkholtz, L.M.; Haynes, R.K.; N’Da, D.D. Straightforward conversion of decoquinate into
inexpensive tractable new derivatives with significant antimalarial activities. Bioorg. Med. Chem. Lett. 2016, 26, 3006–3009. [CrossRef]
20. Ginsburg, A.S.; Grosset, J.H.; Bishai, W.R. Fluoroquinolones, tuberculosis, and resistance. Lancet Infect. Dis. 2003, 3, 432–442. [CrossRef]
21. Wohnsland, F.; Faller, B. High-throughput permeability pH profile and high-throughput alkane/water log P with artificial
membranes. J. Med. Chem. 2001, 44, 923–930. [CrossRef]
Antibiotics 2021, 10, 693 10 of 12
22. Nam, J.; Beales, P.A.; Vanderlick, T.K. Giant phospholipid/block copolymer hybrid vesicles: Mixing behavior and domain
formation. Langmuir 2011, 27, 1–6. [CrossRef]
23. Tanner, L.; Haynes, R.K.; Wiesner, L. Accumulation of TB-Active Compounds in Murine Organs Relevant to Infection by
Mycobacterium tuberculosis. Front. Pharmacol. 2020, 11, 724. [CrossRef] [PubMed]
24. Lenaerts, A.; Barry, C.E., III; Dartois, V. Heterogeneity in tuberculosis pathology, microenvironments and therapeutic responses.
Immunol. Rev. 2015, 264, 288–307. [CrossRef]
25. Beteck, R.M.; Seldon, R.; Coertzen, D.; van der Watt, M.E.; Reader, J.; Mackenzie, J.S.; Lamprecht, D.A.; Abraham, M.; Eribez, K.;
Müller, J.; et al. Accessible and distinct decoquinate derivatives active against Mycobacterium tuberculosis and apicomplexan
parasites. Commun. Chem. 2018, 1, 1–11. [CrossRef]
26. Lyons, M.A.; Reisfeld, B.; Yang, R.S.; Lenaerts, A.J. A physiologically based pharmacokinetic model of rifampin in mice. Antimicrob.
Agents Chemother. 2013, 57, 1763–1771. [CrossRef] [PubMed]
27. Ji, B.; Truffot-Pernot, C.; Lacroix, C.; Raviglione, M.C.; O’Brien, R.J.; Olliaro, P.; Roscigno, G.; Grosset, J. Effectiveness of rifampin,
rifabutin and rifapentine for preventive therapy of tuberculosis in mice. Am. J. Respir. Crit. Care Med. 1993, 148, 1541–1546.
[CrossRef] [PubMed]
28. Arbex, M.A.; Varella, M.D.C.L.; Siqueira, H.R.D.; Mello, F.A.F.D. Antituberculosis drugs: Drug interactions, adverse effects, and
use in special situations-part 2: Second line drugs. J. Bras. Pneum. 2010, 36, 641–656. [CrossRef] [PubMed]
29. Jayaram, R.; Shandil, R.K.; Gaonkar, S.; Kaur, P.; Suresh, B.; Mahesh, B.; Jayashree, R.; Nandi, V.; Bharath, S.; Kantharaj, E.
Isoniazid pharmacokinetics-pharmacodynamics in an aerosol infection model of tuberculosis. Antimicrob. Agents Chemother. 2004,
48, 2951–2957. [CrossRef]
30. Grosset, J.; Ji, B. Experimental chemotherapy of mycobacterial diseases. In Mycobacteria; Springer: Berlin/Heidelberg, Germany,
1998; pp. 51–97.
31. Lakshminarayana, S.B.; Huat, T.B.; Ho, P.C.; Manjunatha, U.H.; Dartois, V.; Dick, T.; Rao, S.P. Comprehensive physicochemical,
pharmacokinetic and activity profiling of anti-TB agents. J. Antimicrob. Chemother. 2015, 70, 857–867. [CrossRef]
32. Dheda, K.; Gumbo, T.; Gandhi, N.R.; Murray, M.; Theron, G.; Udwadia, Z.; Migliori, G.B.; Warren, R. Global control of tuberculosis:
From extensively drug-resistant to untreatable tuberculosis. Lancet Respir. Med. 2014, 2, 321–338. [CrossRef]
33. Warner, D.F.; Mizrahi, V. Shortening treatment for tuberculosis–to basics. N. Engl. J. Med. 2014, 371, 1642–1643. [CrossRef]
34. Cho, H.-W.; Kim, S.B.; Jeong, M.K.; Park, Y.; Miller, N.; Ziegler, T.; Jones, D. Discovery of metabolite features for the modelling
and analysis of high-resolution NMR spectra. Int. J. Data Min. Bioinform. 2008, 2, 176–192. [CrossRef]
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